IXICO Secures £1.3 Million in New Contracts Covering Nearly Full Revenue Forecast
Neuroscience imaging company IXICO has secured two new contracts totaling £1.3 million that are expected to nearly fully cover its current-year revenue forecast of £7.5 million for the year ending September 2026. The Alzheimer's biomarker validation contract and extension of a Huntington’s disease trial highlight strong client relationships and align with IXICO's growth strategy.
Topics: Alzheimer's disease biotech Huntington's disease imaging analytics neuroscience